Anti-hepatitis C virus activity of Acacia confusa extract via suppressing cyclooxygenase-2

Antiviral Research

Volumn 89, Issue 1, 2011, Pages 35-42

  Lee, Jin Ching ^a   Chen, Wei Chun ^a   Wu, Shou Fang ^a   Tseng, Chin kai ^a   Chiou, Ching Yi ^a   Chang, Fang Rong ^a   Hsu, Shih hsien ^b   Wu, Yang Chang ^a,c,d  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Acacia confusa; Cyclooxygenase 2; Hepatitis C virus; Nuclear factor kappaB

Indexed keywords

2' METHYLCYTIDINE; ACACIA CONFUSA EXTRACT; ALPHA INTERFERON; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PLANT EXTRACT; RECOMBINANT ALPHA2A INTERFERON; TELAPREVIR; UNCLASSIFIED DRUG;

ACACIA; ACACIA CONFUSA; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ISOLATION; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS INHIBITION;

ACACIA; ANTIVIRAL AGENTS; CYCLOOXYGENASE 2; DRUG SYNERGISM; ENZYME INHIBITORS; HEPACIVIRUS; HUMANS; INTERFERON-ALPHA; PLANT EXTRACTS; VIRUS REPLICATION;

ACACIA CONFUSA; HEPATITIS C VIRUS;

EID: 78650890325     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.11.003     Document Type: Article

References (50)

1. Ahn K.S., Aggarwal B.B. Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann. N. Y. Acad. Sci. 2005, 1056:218-233.
2. Alter M.J. Epidemiology of hepatitis C virus infection. World J. Gastroenterol. 2007, 13:2436-2441.
3. Bassit L., Grier J., Bennett M., Schinazi R.F. Combinations of 2'-C-methylcytidine analogues with interferon-alpha2b and triple combination with ribavirin in the hepatitis C virus replicon system. Antivir. Chem. Chemother. 2008, 19:25-31.
4. Blight K.J., Kolykhalov A.A., Rice C.M. Efficient initiation of HCV RNA replication in cell culture. Science 2000, 290:1972-1974.
5. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regulat. 1984, 22:27-55.
6. Chun K.S., Surh Y.J. Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem. Pharmacol. 2004, 68:1089-1100.
7. El-Bassiouny A.E., Zoheiry M.M., Nosseir M.M., El-Ahwany E.G., Ibrahim R.A., El-Bassiouni N.E. Expression of cyclooxygenase-2 and transforming growth factor-beta1 in HCV-induced chronic liver disease and hepatocellular carcinoma. MedGenMed 2007, 9:45.
8. Ferenci P. Pegylated interferon plus ribavirin for chronic hepatitis C: the role of combination therapy today, tomorrow and in the future. Minerva Gastroenterol. Dietol. 2006, 52:157-174.
9. Gardelli C., Attenni B., Donghi M., Meppen M., Pacini B., Harper S., Di Marco A., Fiore F., Giuliano C., Pucci V., Laufer R., Gennari N., Marcucci I., Leone J.F., Olsen D.B., MacCoss M., Rowley M., Narjes F. Phosphoramidate prodrugs of 2'-C-methylcytidine for therapy of hepatitis C virus infection. J. Med. Chem. 2009, 52:5394-5407.
10. Georgel P., Schuster C., Zeisel M.B., Stoll-Keller F., Berg T., Bahram S., Baumert T.F. Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies. Trends Mol. Med. 2010, 16:277-286.
11. Gretton S., Hughes M., Harris M. Hepatitis C virus RNA replication is regulated by Ras-Erk signalling. J. Gen. Virol. 2010, 91:671-680.
12. Ikeda K., Arase Y., Kobayashi M., Saitoh S., Someya T., Hosaka T., Sezaki H., Akuta N., Suzuki Y., Suzuki F., Kumada H. A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: a cohort study of 1249 patients. Dig. Dis. Sci. 2006, 51:603-609.
13. Kan W.-S. Leguminosae. Manual of Medicinal Plants in Taiwan 1978, vol. 2:239-240. National Research Institute of Chinese Medicine, Taipei, Taiwan.
14. Khattab M.A. Targeting host factors: a novel rationale for the management of hepatitis C virus. World J. Gastroenterol. 2009, 15:3472-3479.
15. Lee J.C., Chang C.F., Chi Y.H., Hwang D.R., Hsu J.T. A reporter-based assay for identifying hepatitis C virus inhibitors based on subgenomic replicon cells. J. Virol. Meth. 2004, 116:27-33.
16. Lee J.C., Tseng C.K., Chen K.J., Huang K.J., Lin C.K., Lin Y.T. A cell-based reporter assay for inhibitor screening of hepatitis C virus RNA-dependent RNA polymerase. Anal. Biochem. 2010, 403:52-62.
17. Lee J.C., Wu T.Y., Huang C.F., Yang F.M., Shih S.R., Hsu J.T. High-efficiency protein expression mediated by enterovirus 71 internal ribosome entry site. Biotechnol. Bioeng. 2005, 90:656-662.
18. Lee J.C., Yu M.C., Lien T.W., Chang C.F., Hsu J.T. High-throughput cell-based screening for hepatitis C virus NS3/4A protease inhibitors. Assay Drug Dev. Technol. 2005, 3:385-392.
19. Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 2006, 25:3834-3847.
20. Li S., Kodama E.N., Inoue Y., Tani H., Matsuura Y., Zhang J., Tanaka T., Hattori T. Procyanidin B1 purified from Cinnamomi cortex suppresses hepatitis C virus replication. Antivir. Chem. Chemother. 2010, 20:239-248.
21. Lin K., Perni R.B., Kwong A.D., Lin C. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Antimicrob. Agents Chemother. 2006, 50:1813-1822.
22. Lindenbach B.D., Rice C.M. Unravelling hepatitis C virus replication from genome to function. Nature 2005, 436:933-938.
23. Liu T., Zaman W., Kaphalia B.S., Ansari G.A., Garofalo R.P., Casola A. RSV-induced prostaglandin E2 production occurs via cPLA2 activation: role in viral replication. Virology 2005, 343:12-24.
24. Lu L., Wei L., Peng G., Mu Y., Wu K., Kang L., Yan X., Zhu Y., Wu J. NS3 protein of hepatitis C virus regulates cyclooxygenase-2 expression through multiple signaling pathways. Virology 2008, 371:61-70.
25. Nunez O., Fernández-Martinez A., Majano P.L., Apolinario A., Gómez-Gonzalo M., Benedicto I., López-Cabrera M., Boscá L., Clemente G., Garcia-Monzón C., Martin-Sanz P. Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins. Gut 2004, 53:1665-1672.
26. Okamoto M., Sakai M., Goto Y., Salim M.T., Baba C., Goto K., Watashi K., Shimotohno K., Baba M. Anti-bovine viral diarrhoea virus and hepatitis C virus activity of the cyclooxygenase inhibitor SC-560. Antivir. Chem. Chemother. 2009, 20:47-54.
27. Peese K. HCV protease inhibitor telaprevir: phase II clinical results. Drug Discov. Today 2009, 15:406.
28. Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.M. Structural biology of hepatitis C virus. Hepatology 2004, 39:5-19.
29. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., Gutkovich-Pyest E., Urieli-Shoval S., Galun E., Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431:461-466.
30. Reynolds A.E., Enquist L.W. Biological interactions between herpesviruses and cyclooxygenase enzymes. Rev. Med. Virol. 2006, 16:393-403.
31. Schaefer M., Mauss S. Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effects. Curr. Drug Abuse Rev. 2008, 1:177-187.
32. Sun B., Karin M. NF-kappaB signaling, liver disease and hepatoprotective agents. Oncogene 2008, 27:6228-6244.
33. Tallarida R.J. Drug synergism: its detection and applications. J. Pharmacol. Exp. Ther. 2001, 298:865-872.
34. Tang T.C., Poon R.T., Lau C.P., Xie D., Fan S.T. Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma. World J. Gastroenterol. 2005, 11:1896-1902.
35. Tazawa R., Xu X.M., Wu K.K., Wang L.H. Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene. Biochem. Biophys. Res. Commun. 1994, 203:190-199.
36. Trujillo-Murillo K., Alvarez-Martinez O., Garza-Rodríguez L., Martínez-Rodriguez H., Bosques-Padilla F., Ramos-Jiménez J., Barrera-Saldana H., Rincón-Sánchez A.R., Rivas-Estilla A.M. Additive effect of ethanol and HCV subgenomic replicon expression on COX-2 protein levels and activity. J. Viral Hepat. 2007, 14:608-617.
37. Trujillo-Murillo K., Rincon-Sanchez A.R., Martinez-Rodriguez H., Bosques-Padilla F., Ramos-Jimenez J., Barrera-Saldana H.A., Rojkind M., Rivas-Estilla A.M. Acetylsalicylic acid inhibits hepatitis C virus RNA and protein expression through cyclooxygenase 2 signaling pathways. Hepatology 2008, 47:1462-1472.
38. Tung W.H., Hsieh H.L., Yang C.M. Enterovirus 71 induces COX-2 expression via MAPKs, NF-kappaB, and AP-1 in SK-N-SH cells: Role of PGE(2) in viral replication. Cell Signal. 2010, 22:234-246.
39. Tung Y.T., Chang S.T. Inhibition of xanthine oxidase by Acacia confusa extracts and their phytochemicals. J. Agric. Food Chem. 2010, 58:781-786.
40. Tung Y.T., Chang S.T. Variation in antioxidant activity of extracts of Acacia confusa of different ages. Nat. Prod. Commun. 2010, 5:73-76.
41. Tung Y.T., Wu J.H., Huang C.C., Peng H.C., Chen Y.L., Yang S.C., Chang S.T. Protective effect of Acacia confusa bark extract and its active compound gallic acid against carbon tetrachloride-induced chronic liver injury in rats. Food Chem. Toxicol. 2009, 47:1385-1392.
42. Tung Y.T., Wu J.H., Huang C.Y., Kuo Y.H., Chang S.T. Antioxidant activities and phytochemical characteristics of extracts from Acacia confusa bark. Bioresour. Technol. 2009, 100:509-514.
43. Wagoner J., Negash A., Kane O.J., Martinez L.E., Nahmias Y., Bourne N., Owen D.M., Grove J., Brimacombe C., McKeating J.A., Pecheur E.I., Graf T.N., Oberlies N.H., Lohmann V., Cao F., Tavis J.E., Polyak S.J. Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology 2010, 51:1912-1921.
44. Wakita T., Pietschmann T., Kato T., Date T., Miyamoto M., Zhao Z., Murthy K., Habermann A., Krausslich H.G., Mizokami M., Bartenschlager R., Liang T.J. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 2005, 11:791-796.
45. Waris G., Siddiqui A. Hepatitis C virus stimulates the expression of cyclooxygenase-2 via oxidative stress: role of prostaglandin E2 in RNA replication. J. Virol. 2005, 79:9725-9734.
46. Wohlfarth C., Efferth T. Natural products as promising drug candidates for the treatment of hepatitis B and C. Acta Pharmacol. Sin. 2009, 30:25-30.
47. Wu J.H., Tung Y.T., Chien S.C., Wang S.Y., Kuo Y.H., Shyur L.F., Chang S.T. Effect of phytocompounds from the heartwood of Acacia confusa on inflammatory mediator production. J. Agric. Food Chem. 2008, 56:1567-1573.
48. Wu J.H., Tung Y.T., Wang S.Y., Shyur L.F., Kuo Y.H., Chang S.T. Phenolic antioxidants from the heartwood of Acacia confusa. J. Agric. Food Chem. 2005, 53:5917-5921.
49. Zhu H., Cong J.P., Yu D., Bresnahan W.A., Shenk T.E. Inhibition of cyclooxygenase 2 blocks human cytomegalovirus replication. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:3932-3937.
50. Zuo G., Li Z., Chen L., Xu X. Activity of compounds from Chinese herbal medicine Rhodiola kirilowii (Regel) Maxim against HCV NS3 serine protease. Antiviral Res. 2007, 76:86-92.